Ixazomib citrate

Ixazomib Citrate is the citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated. It is grouped under the following drug class(es): Antineoplastic agents and Proteasome inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Ninlaro and Ixazomib citrate (Ester). Its PubChem CID is 56844015.